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DObjectives: The clinical translation of tissue-engineered vascular grafts has been demonstrated in children. The
remodeling of biodegradable, cell-seeded scaffolds to functional neovessels has been partially attributed to ma-
trix metalloproteinases. Noninvasive assessment of matrix metalloproteinase activity can indicate graft remod-
eling and elucidate the progression of neovessel formation. Therefore, matrix metalloproteinase activity was
evaluated in grafts implanted in lambs using in vivo and ex vivo hybrid imaging. Graft growth and remodeling
was quantified using in vivo x-ray computed tomography angiography.
Methods: Cell-seeded and unseeded scaffolds were implanted in 5 lambs as inferior vena cava interposition grafts.
At 2 and 6months after implantation, in vivo angiography was used to assess graft morphology. In vivo and ex vivo
single photon emission tomography/computed tomography imagingwas performedwith a radiolabeled compound
targeting matrix metalloproteinase activity at 6 months. The neotissue was examined at 6 months using qualitative
histologic and immunohistochemical staining and quantitative biochemical analysis.
Results: The seeded grafts demonstrated significant luminal and longitudinal growth from 2 to 6 months. In vivo
imaging revealed subjectively greater matrix metalloproteinase activity in grafts versus native tissue. Ex vivo
imaging confirmed a quantitative increase in matrix metalloproteinase activity and demonstrated greater activity
in unseeded versus seeded grafts. The glycosaminoglycan content was increased in seeded grafts versus un-
seeded grafts, without significant differences in collagen content.
Conclusions: Matrix metalloproteinase activity remained elevated in tissue-engineered grafts 6 months after
implantation and could indicate remodeling. Optimization of in vivo imaging to noninvasively evaluate matrix
metalloproteinase activity could assist in the serial assessment of vascular graft remodeling. (J Thorac Cardio-
vasc Surg 2014;148:2227-33)See related commentary on page 2234.Our research team developed the first tissue-engineered
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The Journal of Thoracic and Carheart surgery.2 We are currently conducting the first
Food and Drug Administration–approved clinical trial
examining the safety and efficacy of TEVG implantation
in children within the United States.3 The TEVGs were
constructed with autologous bone marrow mononuclear
cells (BM-MNCs) seeded onto a biodegradable scaffold4
and demonstrated growth potential in vivo,5 making
the grafts ideally suited for application in infants and
children.
The transition of a cell-seeded scaffold to a neovessel is a
process characterized by scaffold degradation as a result
of hydrolysis, cellular infiltration, and extracellular matrix
(ECM) deposition and remodeling.6 Matrix metallo-
proteinases (MMPs) are enzymes thought to play important
roles in tissue homeostasis and functional growth and
might contribute significantly to ECM remodeling during
neovessel formation.6,7 Specifically, MMP-2 and -9 are
basement membrane-degrading MMPs that can play
critical roles in ECM remodeling. Previous postmortem
examinations of TEVGs implanted in a murine model
have demonstrated progressively greater MMP-2 expres-
sion during a 4-week course after TEVG implantation,diovascular Surgery c Volume 148, Number 5 2227
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BM-MNC ¼ bone marrow mononuclear cell
CT ¼ computed tomography
ECM ¼ extracellular matrix
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Dand MMP-9 expression peaked at 1 week after surgery
and had significantly decreased by 4 weeks.6 The
elevated MMP-2 expression within a murine model of
TEVG is consistent with the postmortem findings of
Cummings and colleagues,7 who observed elevated
MMP-2 expression in a lamb model of TEVG implantation;
however, MMP-9 expression also remained elevated for 80
weeks after implantation. These results suggest that MMPs
could play a role in the remodeling of TEVGs and that this
process could be prolonged for many months after
implantation.
The current clinical imaging techniques for the serial
assessment of TEVG remodeling have focused on evalua-
tion of the morphologic changes using x-ray computed to-
mography (CT) and magnetic resonance angiography2,5;
however, these approaches cannot provide information
related to the underlying mechanisms responsible for the
ongoing neovessel formation. Targeted imaging of MMP
activity has been previously demonstrated in animal
models of atherosclerosis,8-12 vascular remodeling,13,14
and myocardial infarction15,16 using single photon
emission CT (SPECT) and magnetic resonance
approaches. Additionally, near-infrared fluorescence imag-
ing has indicated progressive remodeling in a murine
model of TEVG implantation that was associated with
qualitative elevations in MMP-2 and -9 activity.17 The
technetium-99m (99mTc)-labeled tracer, 99mTc-RP805, is
a broad-spectrum MMP-targeted compound used for
SPECT/CT imaging that can localize to the site of ECM re-
modeling and provide an opportunity to serially assess the
progression of TEVG remodeling and the formation of
functional neotissue. Therefore, we hypothesized that
99mTc-RP805 SPECT/CT imaging of MMP activity could
complement standard noninvasive imaging approaches
and might serve as a useful tool for serial assessment of
neovessel formation. To test this hypothesis, we evaluated
the feasibility of in vivo and ex vivo SPECT/CT imaging of
MMP activity within TEVGs in a clinically relevant large
animal model 6 months after TEVG implantation. We
also evaluated the serial changes in TEVG morphology us-
ing CT angiography.2228 The Journal of Thoracic and Cardiovascular SurMETHODS
Graft Scaffold
Scaffolds were constructed using a polyglycolic acid nonwoven sheet
coated with a 50:50 copolymer solution of poly (L-lactic acid-co-ε-capro-
lactone; Gunze Corp, Tokyo, Japan), as previously described.2 Before
seeding, all grafts had a measured luminal diameter of 12 mm, wall thick-
ness of 1.5 mm, and length of 20 mm (Figure 1, A). Graft porosity was
examined using scanning electron microscopy (model XL-30; FEI Co,
Hillsboro, Ore).
Bone Marrow-Derived Cell Isolation
Autologous BM-MNCs were isolated from the iliac crest or femoral
head of 3 juvenile Dover lambs into a heparinized syringe (100 U/mL),
diluted 1:4 in phosphate-buffered saline, and passed through a 100-mm
filter to remove the fat and bone fragments. The bone marrow–phos-
phate-buffered saline solution was added to Histopaque-1077 (Sigma-
Aldrich, St Louis, Mo) for density centrifugation at 1500 rpm for 30
minutes. The BM-MNCs were isolated and subsequently washed with
phosphate-buffered saline and centrifuged (1500 rpm for 10 min) 2 more
times. This cell isolation procedure was performed for each of the 3 lambs
that were implanted with the cell-seeded scaffolds.
Scaffold Seeding
The scaffolds were added to a sterile vacuum seeding setup, as previ-
ously described.18 Pressure of 50 mm Hg was applied to the system,
thereby vacuum seeding the BM-MNCs onto the scaffolds. After seeding,
the scaffolds were placed in autologous serum and incubated for 24 hours
(37C, 5% carbon dioxide, 95% relative humidity, 760 mmHg). A sample
of each graft was stained with Lee’s methylene blue on glycol
methacrylate-fixed tissue to quantify the number of attached cells.Graft Implantation
TEVGs were implanted as inferior vena cava (IVC) interposition grafts
(3 seeded scaffolds; 2 unseeded scaffolds) in 5 juvenile Dover lambs (im-
plantation weight, 22.4  2.3 kg). The lambs were sedated with intramus-
cular acepromazine (0.05 mg/kg), followed by intravenous diazepam (0.2
mg/kg) and ketamine (2.75 mg/kg). Anesthesia was maintained throughout
surgery with 1% to 5% isoflurane and intravenous propofol (25 mg/kg/
min). Perioperative cefazolin (22 mg/kg) was administered. A right thora-
cotomy was performed through the seventh intercostal space. After isola-
tion of the IVC and dissection of the phrenic nerve, heparin (100 IU/kg)
was administered intravenously. The IVC was then clamped for 5 minutes
and unclamped for 2 minutes; this process was repeated 3 times for
adequate conditioning. Next, a 2-cm TEVG was anastomosed (proximally
and then distally) using running monofilament 5-0 suture. Radiopaque
markers were placed at the anastomoses (Figure 1, E). Fibrin sealant (Tis-
seel; Baxter International, Deerfield, Ill) was used for hemostasis. A bupi-
vacaine (Marcaine; Hospira, Lake Forest, Ill) nerve block was given for
intercostal nerves 5 to 9. Layered closure was performed, and the chest
tube was removed in the operating room. Postoperatively, the lambs were
treated with fentanyl patches and flunixin meglumine (Banamine; Merck
Animal Health, Whitehouse Station, NJ) for analgesia. No postoperative
antiplatelets or anticoagulants were given. The Institutional Animal Care
and Use Committee at Yale University approved the use of the lambs
and all procedures. All the lambs received humane care in compliance
with the ‘‘Guide for the Care and Use of Laboratory Animals’’ published
by the National Institutes of Health, Animal Welfare Act, and Animal Wel-
fare Regulations.CTAngiography Imaging and Analysis
In vivo, 64-slice, x-ray CT angiography with iodinated contrast (350
mgI/mL; Omnipaque; GE Healthcare, Little Chalfont, UK) was performedgery c November 2014
FIGURE 1. A, Graft scaffold and (B) scanning electron micrograph of polymer scaffold before surgical implantation. C, Schematic representation of sur-
gical implantation of inferior vena cava interposition graft. Intraoperative photograph (D) before and (E) immediately after surgical implantation of an un-
seeded scaffold. Staples denote proximal and distal anastomoses. RA, Right atrium; RV, right ventricle; LV, left ventricle; IVC, inferior vena cava; TEVG,
tissue engineered vascular graft; LA, left atrium.
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D(Discovery NM-CT 570c, GE Healthcare) in the lambs at 2 and 6 months
after TEVG implantation to assess the graft luminal and longitudinal
growth. After sedation, the lambs were intubated and mechanically venti-
lated (Venturi, Cardiopulmonary Corp, Milford, Conn) with 35% oxygen,
65% nitrous oxide, and 1% to 3% isoflurane. Blood pressure, oxygen satu-
ration, and electrocardiographic signal were continuously monitored dur-
ing each imaging session (IntelliVue MP50; Philips Healthcare, Best,
The Netherlands). Peripheral vein access was established, and a 5F poly-
ethylene catheter was placed for administration of fluids, CT contrast
agent, and radioisotope. Before imaging, all the lambs were fasted over-
night and given an intravenous 500-mL bolus of normal saline to attain eu-
volemia. CT images were acquired at a slice thickness of 0.625 mm at 300
mA and 120 kVp. Intravenous contrast injections were performed with a
power injector (Stellant D; Medrad, Warrendale, Pa) at a constant rate of
3 mL/s and total volume of 30 mL, followed by a 20-mL saline flush at
3 mL/s. The TEVG luminal volume and length were quantified using
commercially available software (Advanced Workstation, version 4.4;
GE Healthcare). Measurement of the TEVG length was standardized by se-
lecting the midpoint of each marker attached to the distal and proximal
anastomoses. Stenosis was defined as a decrease in the luminal diameter
that was>50% of the initial diameter at implantation.
In Vivo Hybrid SPECT/CT Imaging
In vivo single isotope imaging was performed 6 months after IVC graft
implantation for qualitative assessment of MMP activity using hybrid
SPECT/CT with 99mTc-RP805 (Lantheus Medical Imaging, Inc, North
Billerica, Mass). 99mTc-RP805 is a broad-spectrum MMP-targeted com-
pound that binds to the activated exposed catalytic domain of MMP-2,
-3, -7, -9, -12, and -13. Previous work in our laboratory has demonstrated
the various binding characteristics associated with this radiotracer for each
of these MMPs.16 SPECTwas performed 60 minutes after intravenous in-
jection of the radiotracer at rest (1468.9  159.1 MBq). All images were
acquired using a dedicated cardiac SPECT camera (Discovery 570c; GE
Healthcare) at a 4-mm slice thickness. Immediately after each SPECT
acquisition, noncontrast-enhanced CT images were acquired and recon-
structed using filtered back projection to create CT attenuation maps.
The SPECT images were reconstructed with a maximum a posteriori algo-
rithm at 80 iterations using commercially available software (Xeleris; GE
Healthcare). Smoothing parameters were selected as b¼ 0.2 and a¼ 0.41.
The images were reconstructed with a dimension of 150 3 150 3 150The Journal of Thoracic and Carvoxels to alleviate artifacts that can result from truncated projections
from the limited field-of-view associated with this SPECT system.19 The
attenuation map was incorporated into the reconstruction for attenuation
correction. No postfiltering was applied to preserve the image resolution.
Ex Vivo SPECT/CT and Quantification
Ex vivo 99mTc-RP805 SPECT/CT was performed immediately after
graft explantation. The grafts were placed on a conical tube to allow for
circumferential visualization and differentiation of MMP activity in the
graft wall. Immediately after each SPECT acquisition, noncontrast-
enhanced CT images were acquired, as previously described. The SPECT
images were reconstructed at a 2-mm slice thickness using the same recon-
struction configuration as specified previously. The total counts were re-
corded on axial slices of the explanted graft and adjacent native IVC
using the vendor’s software (Xeleris; GE Healthcare) and normalized to
the cross-sectional area of tissue for each axial slice. Retention of 99mTc-
RP805 within the graft tissue and native IVC was expressed as a ratio
(TEVG/native IVC).
Histologic Assessment
After surgical explantation and imaging, portions of the TEVG tissue
and native IVC were fixed in 10% formalin and embedded in paraffin.
Next, 5-mm sections, sampled from the midsection of the TEVG, were
stained using standardized techniques for hematoxylin and eosin, Masson’s
trichrome (collagen), Alcian blue (glycosaminoglycans), and elastica van
Gieson (elastin).
Biochemical Assessment
The collagen content was determined for the TEVG and native IVC tis-
sue in triplicate using a Sircol soluble collagen assay (Biocolor Ltd, Car-
rickfergus, United Kingdom) according to the manufacturer’s
instructions. The glycosaminoglycan content was determined in triplicate
using a Blyscan colorimetric assay (Biocolor Ltd) in a similar fashion.
Statistical Analysis
Statistical analysis was performed using commercially available soft-
ware (GraphPad Prism, version 6.00, for Mac OS X; GraphPad Software,
La Jolla, Calif). Paired t tests were used to evaluate the serial changes in
luminal volume and graft length (determined from CT angiography) indiovascular Surgery c Volume 148, Number 5 2229
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in the CT angiography, ex vivo 99mTc-RP805 SPECT/CT, and biochem-
ical results between the seeded and unseeded grafts. Data are expressed
as the mean  standard deviation, unless stated otherwise. A biostatisti-
cian at the Research Institute, Nationwide Children’s Hospital (Colum-
bus, Ohio) reviewed all statistical analyses for proper methodology
and interpretation.RESULTS
Graft Scaffold and Cell Seeding
The scaffold matrix was approximately 80% porous,
with pore diameters ranging from 20 to 100 mm (Figure 1,
B). Isolation and seeding of the BM-MNCs onto the graft
scaffolds (n ¼ 3) resulted in the attachment of 3189 
2337 cells/mm2 before surgical implantation. All 5 lambs
survived the duration of the 6-month study without any
graft-related complications.CTAngiography
In vivo CTangiography demonstrated graft patency in all
the lambs at 2 and 6 months after implantation (Figure 2).
The seeded grafts had a significantly greater luminal vol-
ume at 6 months than at 2 months after implantation (2
months, 2.9  0.9 cm3; 6 months, 3.7  0.9 cm3;
P<.001). They also demonstrated significant longitudinal
growth from 2 to 6 months (2 months, 22.3  1.2 mm; 6
months, 26.0  2.0 mm; P ¼ .03).FIGURE 2. In vivo computed tomography angiography at 2 and 6 months afte
graft patency (lumen indicated by red markers). Serial quantification of compu
neered vascular graft (TEVG) (C) luminal volume and (D) length in seeded gra
2230 The Journal of Thoracic and Cardiovascular SurIn Vivo and Ex Vivo 99mTc-RP805 SPECT/CT
In vivo SPECT/CT demonstrated an increase in 99mTc-
RP805 activity within the region of the IVC graft
(Figure 3). Quantitative analysis of the ex vivo SPECT/
CT images demonstrated greater 99mTc-RP805 activity
within the TEVG than in the adjacent native IVC and signif-
icantly greater relative tracer uptake in the unseeded than in
the seeded grafts (TEVG/native vessel, unseeded, 2.8 0.4;
seeded, 1.8  0.3; P ¼ .03; Figure 4).Histologic Examination
Histologic examination was performed on the TEVG and
native IVC tissue at 6 months after implantation to assess
neotissue cellularity and the presence of collagen, glycos-
aminoglycans, and elastic fiber formation (Figure 5). Tissue
staining with Masson’s trichrome and hematoxylin and
eosin demonstrated that the polymer had degraded by 6
months and had subsequently been replaced by a
collagen-dominated neotissue. Alcian blue staining sug-
gested increased glycosaminoglycan content in the seeded
graft neotissues compared with the unseeded, with the gly-
cosaminoglycans inhomogeneously distributed in the un-
seeded grafts (Figure 5, B). Elastica van Gieson staining
demonstrated mild, but comparable, elastic fiber formation
between the seeded and unseeded groups, with both remain-
ing inferior to the native IVC (Figure 5).r implantation of (A) an unseeded and (B) a seeded scaffold demonstrating
ted tomography angiography revealed significant increases in tissue engi-
fts.
gery c November 2014
FIGURE 3. Increased technetium-99m–labeled RP805 activity was observed in the blood pool and region of inferior vena cava graft implantation (yellow
marker) in (A) axial, (B) sagittal, and (C) coronal views.




No significant differences were observed in the collagen
content within the seeded (n ¼ 3, 65.2  47.8 mg/mg) and
unseeded (n¼ 2, 110.0 11.8 mg/mg) TEVGs. The glycos-
aminoglycan content was significantly greater in the seeded
TEVG group (n¼ 3, 6.5 0.3 mg/mg) than in the unseeded
TEVG group (n ¼ 2, 4.1  0.8 mg/mg; P ¼ .01).
DISCUSSION
In the present study, we have demonstrated the feasibility
of targeted SPECT/CT for the quantitative assessment of
MMP activity within surgically implanted IVC interposi-
tion grafts with complementary serial evaluation of the graft
morphologic changes using in vivo CT angiography. We
used a previously validated lamb model of IVC graft im-
plantation,5 and the density centrifugation technique for
isolation of BM-MNCs met the same criteria for scaffold
cell attachment implemented in our ongoing clinical trial.3
All grafts were patent at 2 and 6 months after implantation,
with the seeded grafts demonstrating significant luminal
and longitudinal growth (Figure 2). Significantly greater
MMP activity was found in the grafts compared with the
native IVC tissue at 6 months after implantation, with
significantly greater MMP activity in the unseeded than in
the seeded grafts (Figure 4). The elevated MMP activityFIGURE 4. Ex vivo single photon emission computed tomography/computed
sample of explanted tissue engineered vascular graft (TEVG) and native inferi
demonstrated heterogeneous uptake of technetium-99m–labeled RP805 (99mTc-
wall in both (B) unseeded and (C) seeded grafts. D, Significantly greater matrix m
The Journal of Thoracic and Carin the grafts might have been related to ongoing neotissue
formation that persisted at a greater level in the unseeded
graft scaffolds at 6 months. The combined imaging tech-
niques of CT angiography and hybrid SPECT/CT offer a
potentially novel approach for the noninvasive, serial eval-
uation of ongoing graft remodeling and neotissue formation
in tissue-engineered grafts.
Previous studies from our laboratory have indicated that
neotissue formation occurs by way of an early
inflammatory-mediated phase of vascular remodeling as
the polymeric scaffold degrades.20-22 The balance of the
production and removal of structurally significant ECM
constituents (eg, collagen, elastin, glycosaminoglycans)
and the degradation of the implanted graft scaffold will
dictate the vascular neotissue evolution. MMPs play an
important role in this balance. Therefore, monitoring
MMP activity could provide valuable information related
to the status of neotissue development in the setting of
TEVG implantation. Two previous studies have quantified
MMP activity within TEVGs implanted as IVC
interposition grafts; however, these studies required
histologic evaluation of the explanted neotissue.6,7 In the
present study, we sought to evaluate the feasibility of the
noninvasive assessment of MMP activity in a clinically
relevant large animal model of TEVG implantation. Wetomography (SPECT/CT) imaging and quantification. A, Representative
or vena cava (IVC) tissue before ex vivo SPECT/CT imaging. SPECT/CT
RP805) in the graft, illustrated by representative cross sections of the vessel
etalloproteinase activity was seen in the unseeded than in the seeded grafts.
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FIGURE 5. Hematoxylin and eosin (H&E), elastica van Gieson (EVG), Masson’s trichrome (trichome), and Alcian blue (Al. Blue) staining of (A) native
inferior vena cava (IVC), (B) unseeded tissue engineered vascular (TEVG) at 6 months, and (C) seeded TEVGs at 6 months. The implanted scaffolds had
completely degraded within 6 months and had been replaced by collagen-dominated neotissue (B and C). Elastic fiber formation was comparable in the
TEVGs but appeared suboptimal compared with the native IVC (A). Alcian blue staining demonstrated a greater amount of glycosaminoglycans in the
seeded than in the unseeded TEVGs.
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implantation at 6 months after implantation using in vivo
SPECT/CT (Figure 3) of a broad-spectrum MMP-targeted
radiotracer (99mTc-RP805). Although increased radiotracer
activity was observed with in vivo SPECT/CT imaging, it
was clear that much of this activity remained in the blood
pool during the point of image acquisition at 1 hour after
radiotracer injection, complicating the quantification of
MMP activity in the graft at this early point after radiotracer
injection (Figure 3). Improved in vivo localization and
quantification of 99mTc-RP805 in the vascular wall might
be achieved in future studies with the incorporation of a
later image acquisition time (2-4 hours after radiotracer in-
jection), as indicated by previous attempts at SPECT/CT
vascular imaging of MMP activity.11,13 Additionally,
in vivo SPECT/CT imaging was not performed with
cardiac gating, limiting the ability to quantify local MMP
activity within the region of TEVG implantation.
Although limitations were present with in vivo SPECT/
CT imaging that prevented quantification of TEVG radio-
tracer uptake, the MMP activity was quantified in TEVGs
and native IVCs using ex vivo SPECT/CT imaging. Sig-
nificant differences in MMP activity were found between
the unseeded and seeded TEVGs at 6 months (Figure 4).
Previous investigation in our laboratory has demonstrated
the importance of cell seeding in the TEVG remodeling
process and identified greater rates of stenosis in the un-
seeded than in the seeded scaffolds23; however, no evi-
dence of aneurysm or stenosis was apparent in the
unseeded or seeded scaffolds in the present study. Serial
in vivo CT angiography demonstrated significant luminal
and longitudinal growth in the seeded scaffolds from 22232 The Journal of Thoracic and Cardiovascular Surto 6 months (Figure 2). This noted growth of TEVGs in
the present study is consistent with previously reported re-
sults from our laboratory that identified serial changes in
TEVG growth using magnetic resonance angiography in
juvenile lambs.5 The patterns of longitudinal growth
measured by CT angiography suggest that implanted scaf-
folds will have biodegraded by 6 months and allowed for
growth of newly formed neotissue within juvenile lambs
that nearly doubled in weight during the 6-month study
period (implantation weight, 22.4  2.3 kg; 6-month
weight, 42.7  4.3 kg).
Histologic evaluation of the TEVG tissue at 6 months af-
ter implantation confirmed graft scaffold degradation and
subsequent replacement by a collagen-dominant neotissue
(Figure 5). Although no significant differences in collagen
content were identified on biochemical analysis, the lower
collagen content and increased MMP activation in the
TEVGs than in the native IVC tissue suggests that ECM re-
modeling continued at 6 months after implantation and that
the neotissue was still actively remodeling. Elastica-van
Gieson staining demonstrated mild, but comparable, elastic
fiber formation between the seeded and unseeded neotissue
(Figure 5), although both TEVG groups remained inferior
to the native IVC tissue. These histologic observations
have indicated continued ECM remodeling that corre-
sponds with the SPECT/CT findings of increased MMP ac-
tivity at 6 months after TEVG implantation. Improved
in vivo SPECT/CT imaging for the noninvasive assessment
of MMP activity should greatly facilitate our understanding
of the period associated with neotissue formation and
enhance the application of tissue engineering within the car-
diovascular system.gery c November 2014




A small number of lambs were used in the present study.
Although these numbers were sufficient for a feasibility
study, future investigations with a greater number of im-
plantations will be necessary to increase the statistical po-
wer and evaluate the full potential of noninvasive imaging
of MMPs in vascular grafts. Additionally, in vivo SPECT
imaging was not optimized for localization and quantifica-
tion of MMP activity. SPECT imaging protocols that incor-
porate cardiac gating and later acquisition times after
radiotracer injection should provide improved localization
of radiotracer activity and allow for noninvasive in vivo
quantification of MMP activity within TEVGs. Although
the present study evaluated the feasibility of noninvasive
imaging of MMP activity for the detection of ongoing
TEVG remodeling, immunohistochemistry was not per-
formed. Such an analysis might have provided additional
insight into the presence of specific MMPs within the neo-
tissue at 6 months after implantation. Future investigations
targeted at the TEVG remodeling process could greatly
benefit from correlative immunohistochemistry findings to
validate the noninvasive molecular imaging findings.CONCLUSIONS
The present study has demonstrated the feasibility of tar-
geted SPECT/CT imaging of MMP activity within TEVGs
implanted in a growing large animal model. The ability to
noninvasively assess MMP activity within TEVGs in vivo
could provide a unique opportunity to evaluate the underly-
ing mechanisms regulating the transition from TEVG to
neovessel and might assist with improved translation of tis-
sue engineering into clinical practice.
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